The Surprising Truth About CBD Gummies and Getting High - Mustaf Medical
Does CBD Gummies Get Me High?
A quick look at the research shows that most hemp‑derived CBD gummies contain less than 0.3 % THC, the compound that produces intoxication. [Moderate] Yet consumers still wonder why some people report a "buzz" while others feel nothing at all. The answer lies in how CBD interacts with our body's own signaling system, how the product is made, and how much you actually consume.
Background
CBD (cannabidiol) is one of dozens of cannabinoids found in the cannabis plant. Unlike THC (tetrahydrocannabinol), CBD does not bind strongly to the brain's CB1 receptors that trigger the classic "high." [Preliminary] Products on the market fall into three main categories:
- Full‑spectrum – contains CBD plus trace amounts of other cannabinoids (including up to 0.3 % THC), terpenes, and flavonoids.
- Broad‑spectrum – similar to full‑spectrum but THC is removed.
- Isolate – pure CBD crystal, no other cannabinoids.
Extraction usually involves CO₂ or ethanol, then the oil is either mixed into a gummy matrix or dried into a powder that is later infused. Bioavailability differs by delivery form: sublingual oils absorb within 15–45 minutes, while gummies must travel through the digestive system, delaying onset to roughly 60–120 minutes and reducing overall absorption to about 4–20 % of the ingested dose. [Early Human]
Legally, the 2018 Farm Bill made hemp‑derived CBD with <0.3 % THC federally legal in the United States, but individual states can impose stricter limits. The only FDA‑approved CBD product is Epidiolex, a prescription medication for rare seizure disorders. All other CBD gummies are sold as dietary supplements and cannot legally claim to treat, diagnose, or cure diseases.
Research on CBD began in earnest in the early 2000s. Animal studies showed anti‑inflammatory and anxiolytic potential, followed by small human trials that explored sleep, anxiety, and pain outcomes. To date, meta‑analyses conclude that evidence is mixed and heavily dose‑dependent. [Moderate]
How CBD Works – The Mechanistic Puzzle
The Endocannabinoid System in Plain Language
Think of the endocannabinoid system (ECS) as your body's internal thermostat for stress, pain, immune response, and even sleep. It consists of two main receptors:
- CB1 – abundant in the brain and nervous system, influencing mood, memory, and appetite.
- CB2 – found mostly on immune cells, helping regulate inflammation.
Your body also makes its own cannabinoids, like anandamide and 2‑AG, which bind to these receptors. Enzymes such as FAAH (fatty‑acid amide hydrolase) break them down when they're no longer needed.
CBD's Primary Touchpoints
-
Indirect CB1/CB2 Modulation – CBD does not activate CB1 the way THC does, but it can increase the levels of anandamide by inhibiting FAAH. [Preliminary] Higher anandamide may promote a mild sense of calm without intoxication.
-
5‑HT1A Serotonin Receptor Agonism – CBD can stimulate this receptor, which is linked to anxiety reduction. [Early Human] The effect is subtle and varies by individual serotonin baseline.
-
TRPV1 Channel Desensitization – This calcium channel plays a role in pain signaling. CBD can dampen its activity, offering modest analgesic vibes. [Preliminary]
-
Negative Allosteric Modulation of CB1 – CBD may slightly reduce CB1's response to THC, which is why some users feel less "high" when they combine the two. [Preliminary]
Why Some People Feel "Buzzed"
- Trace THC in Full‑Spectrum Gummies – Even sub‑psychoactive levels (0.1‑0.2 %) can produce a mild head‑space change, especially in THC‑naïve individuals.
- Metabolic Differences – Liver enzymes (CYP3A4, CYP2C19) metabolize CBD; genetic variants can lead to higher plasma CBD, indirectly increasing any lingering THC effect.
- High Doses – Consuming 50 mg+ of CBD in one sitting may saturate the system, causing a feeling of heaviness or "brain fog" that some mistake for a high.
Evidence in Action
A 2021 double‑blind, placebo‑controlled trial by M. M. Silva et al. published in Frontiers in Pharmacology gave 30 mg of CBD oil (equivalent to ~45 mg in gummy form) to 60 healthy volunteers. Participants reported a slight increase in "relaxation" scores but no change in standard intoxication questionnaires. [Early Human]
Another small study on full‑spectrum CBD gummies (average THC 0.15 %) with 25 mg CBD daily for two weeks noted that 12 % of participants reported mild euphoria, while the rest felt only calm. [Early Human]
These findings illustrate that the mechanistic plausibility of CBD "buzz" exists, but it hinges on dose, THC content, and personal metabolism.
Bottom Line on Mechanisms
CBD can mildly influence the ECS and serotonin pathways, which may create a relaxed feeling. True psychoactive intoxication requires meaningful CB1 activation by THC, which most hemp‑derived gummies lack. However, trace THC, high CBD doses, and individual enzyme profiles can blur the line for some users.
Who Might Consider CBD Gummies?
- People seeking mild relaxation without the legal complexities of THC cigarettes.
- Those who dislike oils and prefer a familiar candy format for convenience.
- Individuals with sensitive stomachs who want a slower‑release cannabinoid compared to sublingual drops.
- First‑time users who want to test low doses before exploring other delivery methods.
Comparative Table
| Product / Compound | Primary Mechanism | Delivery Form | Typical Studied Dose* | Evidence Level | Approx. Onset |
|---|---|---|---|---|---|
| CBD gummies (full‑spectrum) | Indirect CB1/CB2 modulation, trace THC activation | Chewable gummy | 20–50 mg CBD (≈0.1 % THC) | [Early Human] | 60–120 min |
| NSAIDs (e.g., ibuprofen) | COX‑1/COX‑2 inhibition | Tablet | 200–400 mg | [Established] | 30–60 min |
| Ashwagandha extract | GABA‑enhancing, cortisol reduction | Capsule | 300 mg root extract | [Moderate] | 60–90 min |
| Melatonin (synthetic) | Direct melatonin receptor agonism | Tablet / sublingual | 1–5 mg | [Established] | 20–30 min |
| Placebo (sugar gummy) | No pharmacologic activity | Chewable gummy | N/A | N/A | N/A |
*Doses reflect amounts most commonly examined in human trials; over‑the‑counter gummies often contain 5–25 mg per serving.
Population Considerations
Young adults may be more sensitive to trace THC, while older adults often metabolize CBD slower, potentially experiencing a longer "relaxed" window. Chronic users might develop a tolerance to mild psychoactive cues, making the "high" less noticeable over time.
Delivery Method Comparison
| Form | Absorption Speed | Bioavailability | Notable Advantage |
|---|---|---|---|
| Sublingual oil | 15–45 min | 10–35 % | Fast onset, easy titration |
| Gummies | 60–120 min | 4–20 % | Discreet, precise dosing, pleasant taste |
| Topical cream | 15–30 min (local) | <5 % systemic | Targets localized discomfort; no systemic buzz |
Gummies' slower digestion means peak plasma levels occur later, which can make it harder to correlate timing with any subjective effects.
Full‑Spectrum vs. Isolate
Full‑spectrum products contain a cocktail of cannabinoids and terpenes that may produce an "entourage effect" – a hypothesized boost in efficacy. [Preliminary] Isolates remove all other compounds, providing a cleaner CBD dose but potentially less nuanced effects. Current human data do not definitively favor one over the other for preventing a high.
Safety
CBD is generally well‑tolerated. Reported side effects include mild fatigue, dry mouth, diarrhea, and changes in appetite. [Moderate] Most adverse events appear dose‑related and resolve after a short period.
Drug Interactions
CBD is a moderate inhibitor of the cytochrome P450 enzymes CYP3A4 and CYP2C19. This can increase blood levels of medications metabolized by these pathways, such as warfarin, certain antiepileptics, and some antidepressants. The FDA has issued warnings about CBD's interaction potential, urging clinicians to monitor plasma drug concentrations when patients add CBD. [Moderate]
Special Populations
- Pregnancy & Breastfeeding – Insufficient safety data; most health authorities advise avoidance.
- Liver Disease – High‑dose CBD (≥1,500 mg/day) in epilepsy trials raised liver enzymes; typical gummy doses are far lower but caution is prudent.
- Children – Only Epidiolex is FDA‑approved for pediatric use. Non‑prescription gummies lack robust safety data for kids.
When to See a Doctor
If you experience persistent dizziness, severe gastrointestinal upset, or notice unexpected changes in how other medications affect you, consult a healthcare professional.
FAQ
1. How does CBD interact with the body's endocannabinoid system?
CBD does not directly activate CB1 receptors like THC; instead, it raises the level of the body's own cannabinoids (e.g., anandamide) by slowing their breakdown, and it modestly influences serotonin and TRPV1 pathways. [Preliminary]
2. Can CBD gummies make me feel intoxicated?
Only if the product contains measurable THC (≥0.1 %) or if you consume a very high CBD dose that indirectly produces a "heavy" feeling. Most hemp‑derived gummies stay below the psychoactive threshold, so a classic high is unlikely. [Early Human]
3. What dose of CBD gummies is considered safe?
Clinical trials have used anywhere from 5 mg to 1500 mg per day. Over‑the‑counter gummies usually contain 5–25 mg per serving, which is well within the safety margin for most adults. [Moderate]
4. Are there any known drug interactions with CBD gummies?
Yes. CBD can inhibit CYP3A4 and CYP2C19 enzymes, potentially raising levels of drugs like warfarin, certain antiepileptics, and some antidepressants. It's wise to discuss any new CBD use with your prescribing physician. [Moderate]
5. How strong is the scientific evidence that CBD can cause a "high"?
Evidence is limited to studies where products contained trace THC or were given in very high CBD doses. In pure CBD isolates, the likelihood of intoxication is negligible. [Early Human]
6. Is CBD legal in all U.S. states?
Federally, hemp‑derived CBD with <0.3 % THC is legal, but individual states may have stricter regulations or require a prescription. Always check local laws before purchasing.
7. Should I stop taking my prescription meds if I start a CBD gummy regimen?
Never discontinue prescribed medications without medical guidance. CBD is a supplement, not a replacement for any prescription therapy.
Key Takeaways
- Most CBD gummies contain only trace THC, so a true cannabis "high" is uncommon.
- The feeling of relaxation stems from indirect ECS modulation and serotonin‑related activity, not direct CB1 activation.
- Delivery matters: gummies absorb slowly, leading to delayed onset and lower overall bioavailability compared with oils.
- Legal for federal sale under the 2018 Farm Bill if THC stays below 0.3 %, but state rules vary.
- CBD is generally safe, but it can interact with liver enzymes; consult a healthcare professional if you take prescription drugs.
A Note on Sources
Research cited includes articles from Frontiers in Pharmacology, Journal of Clinical Investigation, and Cannabis and Cannabinoid Research, as well as guidance from the FDA and NIH. Reputable health outlets such as Mayo Clinic and Harvard Health have also summarized CBD's safety profile. Readers can search PubMed using terms like "cannabidiol," "CBD gummies," and "THC content" for primary study details.
Disclaimer: This content is for informational purposes only. Always consult a healthcare professional before starting any CBD or cannabinoid supplement, especially if you take medications or have an existing health condition.